Morgan Stanley 13D and 13G filings for Arbutus Biopharma Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-03 3:26 pm Purchase |
2024-12-31 | 13G | Arbutus Biopharma Corporation ABUS |
MORGAN STANLEY MS |
21,524,661 11.400% |
2,132,173 (+10.99%) |
Filing |
| 2024-06-10 4:50 pm Purchase |
2024-05-31 | 13G | Arbutus Biopharma Corporation ABUS |
MORGAN STANLEY MS |
19,392,488 10.300% |
17,954,224 (+1248.33%) |
Filing |
| 2021-02-10 12:13 pm Sale |
2020-12-31 | 13G | Arbutus Biopharma Corporation ABUS |
MORGAN STANLEY MS |
1,438,264 1.700% |
-2,059,314 (-58.88%) |
Filing |
| 2020-07-16 4:22 pm Purchase |
2020-07-07 | 13G | Arbutus Biopharma Corporation ABUS |
MORGAN STANLEY MS |
3,497,578 5.100% |
3,497,578 (New Position) |
Filing |